On March 24, 2016, the final open label experimental treatment session was completed in our Israeli Phase 2 study of MDMA-assisted psychotherapy for PTSD. In addition to being the final experimental session in this study, it was also the final experimental session in Phase 2 of MAPS’ plan to develop MDMA-assisted psychotherapy into a legal treatment for PTSD. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study has treated 10 subjects with chronic, treatment-resistant PTSD from any cause. Once the final evaluations are complete, we will gather data for inclusion in an international meta-analysis of the safety and efficacy of MDMA-assisted psychotherapy for the treatment of PTSD.
